Yi Larson - 11 Jun 2025 Form 4 Insider Report for Olema Pharmaceuticals, Inc. (OLMA)

Source evidence Original filing metadata and source links for verification. 5 source fields
SEC form
4
Accepted by SEC
13 Jun 2025, 17:00:33 UTC
Prior SEC filing
18 Jun 2024
Next SEC filing
23 Jun 2026
Source filing
View source filing
Reporting owner 1 detail
Reporting owner signature
/s/ Shane Kovacs, Attorney-in-fact

Key filing fact

Yi Larson filed Form 4 for Olema Pharmaceuticals, Inc. (OLMA) on 13 Jun 2025.

Key facts

  • This page summarizes Yi Larson's Form 4 filing for Olema Pharmaceuticals, Inc. (OLMA).
  • 1 reported transaction and 1 derivative row are listed below.
  • Accepted by SEC: 13 Jun 2025, 17:00.

Change

  • Previous filing in this sequence was filed on 18 Jun 2024.
  • Current net transaction value: $0.

Research use

  • This tells you what this filing adds before you inspect full transaction and derivative tables.
  • You can trace every row back to the original SEC filing document.

Evidence

Filed on Form 4

Ownership activity is grounded in SEC Form 4 disclosures.

View source filing

Reporting Owners (1)

CIK 0001785987 Primary reporting owner

Larson Yi

Relationship
Director
Address
C/O OLEMA PHARMACEUTICALS, INC., 780 BRANNAN ST, SAN FRANCISCO
Signature
/s/ Shane Kovacs, Attorney-in-fact
Signature date
13 Jun 2025

Reported derivative securities

Options, warrants, convertible securities, or similar derivative positions disclosed in the filing.

OLMA transaction Derivative

Stock Option (right to buy)

Award

Transaction value
$0
Shares
+24,150
Change %
Price
$0.000000
Shares after
24,150
Date
11 Jun 2025
Ownership
Direct
Underlying class
Common Stock
Underlying amount
24,150
Exercise price
$4.08
Footnotes
F1
* marks a reported price that did not pass the local price check.

Additional SEC filing notes

Filing notes and footnotes

Explanation of responses 1 footnote

Footnote F1

The shares subject to the option vest in a series of 12 successive equal monthly installments measured from June 11, 2025, subject to the Reporting Person's continuous service through each applicable vesting date. Such shares vest in full on the date of the Issuer's next annual meeting of stockholders if such stock option is not otherwise fully vested by such date, subject to the Reporting Person's continuous service through such vesting date.

We use cookies and similar technologies to provide certain features, enhance the user experience and, if you allow them, measure engagement and deliver advertising. Analytics and marketing storage stay off until you grant consent. By clicking on "Agree and continue", you declare your consent to the use of the selected optional cookies. Manage preferences to update or revoke optional consent for future visits. For more information, see our Privacy Policy .